Bacterin International Holdings (AMEX:BONE) said Wednesday that a peer review article in the Dove Press Journal concluded its OsteoSponge allograft shows ideal properties for bone regeneration and is superior to autografts, or the graft of a patient's own bone.
"We are very pleased to share this paper with surgeons, materials
managers, and distributors that not only is OsteoSponge equal to, but
offers attributes even better than, the patient's own bone, for graft
procedures," chief executive Guy Cook said in a statement.
"The OsteoSponge product was and still is a revolutionary concept in
the field of bone grafting and this paper is another step in validating
our collective efforts."
The OsteoSponge allograft consists of 100 percent demineralized human
cancellous bone, with no additional carrier materials. The material is
prepared using methods that preserve native growth factors, thereby
promoting cellular ingrowth, proliferation, and ultimately osteogenesis.
The product has been used in over 100,000 procedures.
Dove Press also noted in its article that there was no risk of complication at the harvest site, or donor pain post-operatively.
Furthermore, the article explains the rational and characteristics
for OsteoSponge, summarizing data from preclinical and human studies.
It also includes a discussion of the strengths and limitations of the
different types of bone graft for the treatment of bone defects.
The paper titled “Rational, characteristics and clinical performance
of the OsteoSponge: a novel allograft for treatment of osseous defects"
can be downloaded here: http://www.dovepress.com/articles.php?article_id=9619
The company, which has about 117 employees, develops bone graft material and antimicrobial coatings for medical applications.
Its products are used to enhance fusion in spine surgery, as well as
for back pain relief with a facet joint stabilization, and promotion of
bone growth in foot and ankle surgery.